Company profile: Insight Genetics
1.1 - Company Overview
Company description
- Provider of advanced molecular diagnostics for precision cancer care, delivering biopharma services with tissue- and blood-based technologies for biomarker-driven clinical trials; Multiplex PCR and Real Time PCR IVD development; proprietary immune therapy response assays; core lab IVD assay CDx support; target discovery using proprietary assays and NGS subclassification panels; assay design, development and validation.
Products and services
- Assay Design, Development & Validation: Engineers comprehensive programs spanning early-stage tests to clinical trial assays and IVD offerings, executing design, development, and validation workflows within an IVD-focused framework for precision cancer care
- Biopharma Services: Delivers tissue- and blood-based biomarker-driven clinical trial platforms, incorporating immuno-oncology systems, tumor mutational burden (TMB) panels, and next-generation sequencing (NGS) assays within NGS-enabled workflows for biomarker measurement in clinical studies
- Multiplex PCR assay and Real Time PCR IVD development: Develops multiplex PCR and real-time PCR products for in vitro diagnostics, configuring assay formats and performance parameters through PCR-based development services aligned to IVD applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Insight Genetics
Century Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune diseases, including CNTY-101 targeting CD19-positive B-cell lymphomas (Phase 1 ELiPSE-1). Offers CRISPR-MAD7 mediated HDR gene editing, Allo-Evasion technology for immune evasion and repeat dosing, CAR and protein engineering, and common engineered iPSC progenitors to accelerate development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Century Therapeutics company profile →
Endocare
HQ: United States
Website
- Description: Provider of medical devices and related consumables for cryoablation, developing, manufacturing, and distributing these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endocare company profile →
Alethia Biotherapeutics
HQ: Canada
Website
- Description: Provider of monoclonal antibody-based therapeutics for cancer-associated diseases, including AB-16B5, a humanized IgG2 antibody targeting secreted clusterin to inhibit EMT, enhance chemotherapy response, and reduce tumor invasion; AB-3A4, developed as an ADC targeting KAAG1 for ovarian and triple-negative breast cancers; and STAR technology for discovering differentially expressed mRNA sequences, including rare ones, to identify novel therapeutic targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alethia Biotherapeutics company profile →
Cirrus Bio
HQ: United States
Website
- Description: Provider of solutions for common health issues that impact well-being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cirrus Bio company profile →
F-star
HQ: United Kingdom
Website
- Description: Provider of novel bispecific antibody therapeutics focused on immuno-oncology and oncology, developing bispecific antibody products to improve the standard of care, with the ability to create and develop Fcab™ antibody fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full F-star company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Insight Genetics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Insight Genetics
2.2 - Growth funds investing in similar companies to Insight Genetics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Insight Genetics
4.2 - Public trading comparable groups for Insight Genetics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →